Abstract
Introduction
Bucillamine is an anti-rheumatic agent that was developed in Japan and released in 1987 (1) and later released in Korea in 1992 . Since then, bucillamine has been used for many patients with RA in Japan and Korea as a popular antirheumatic agent. It is known that bucillamine may cause interstitial pneumonia, and some similar case reports and reviews have been published (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
. L a b o r a t o r y Da t a o n Ad mi s s i o n
F i g u r e 1 . Ch e s t r o e n t g e n o g r a m o n a d mi s s i o n . I n f i l t r a t i v e s h a d o w c a n n o t b e i d e n t i f i e d i n t h e l u n g f i e l d . T h e c e n t r a l v e i n c a t h e t e r wa s i n s e r t e d i n t o t h e s u b c l a v i a n v e i n b e c a u s e o f t h e a n o r e x i a a n d s u b -i r e u s c o n d i t i o n .
CT revealed several patchy ground grass opacities in the bilateral lung fields ( Fig. 2A) 
F i g u r e 2 . ( A) CT s c a n o n a d mi s s i o n . B i l a t e r a l p a t c h y i n f i l t r a t i v e s h a d o ws a r e s e e n i n b o t h l u n g f i e l d s ( wh i t e a r r o ws ) . T h e s h a d o ws d e mo n s t r a t e v e r y l i g h t g r o u n d g r a s s o p a c i t i e s . ( B ) T wo we e k s a f t e r t h e wi t h d r a wa l o f b u c i l l a mi n e , t h e s h a d o ws d i s a p p e a r e d c o mp l e t e l y .

F i g u r e 3 . ( A) I n t h e a l v e o l a r s p a c e s , t e mp o r a l l y h o mo g e n e o u s mu r a l i n c o r p o r a t e d y o u n g f i b r o s i s ( * ) a n d b u d t y p e f i b r o s i s ( b l a c k a r r o wh e a d ) a r e p r e s e n t . Co l l a g e n g l o b u l e s ( wh i t e a r r o wh e a d ) , wh i c h a r e t h e a b s o r p t i o n p r o c e s s o f b u d t y p e i n t r a a l v e o l a r f i b r o s i s , a r e r e c o g n i z e d . T h e s e f i n d i n g s a r e s u g g e s t i v e o f NS I P p a t t e r n f i b r o s i s . ( B ) T h e r e i s l y mp h o c y t e p r e d o mi n a n t i n f l a mma t o r y c e l l i n f i l t r a t i o n i n t h e a l v e o l a r i n t e r s t i t i u m. E o s i n o p h i l s ( b l a c k a r r o wh e a d s ) we r e o c c a s i o n a l l y o b s e r v e d t o i n f i l t r a t e t h e a l v e o l a r i n t e r s t i t i u m. ( C) S wo l l e n a t y p i c a l t y p e I I e p i t h e l i a l c e l l s ( b l a c k a r r o wh e a d )
we r e f o u n d . (6, 7, 12 
Discussion
Pleuropulmonary involvement in RA occurs in about 50% of patients and represents a wide variety of diseases including interstitial pneumonia, airway diseases (bronchiolitis obliterans and follicular bronchiolitis), pleurisy, rheumatoid nodule, and rarely pulmonary vascular disease (13). In addition, some lung diseases are related to the adverse effects of anti-rheumatic agents, such as drug-induced interstitial lung diseases (DILD). Occasionally, it is difficult to discriminate DILD from RA associated interstitial pneumonia, but accurately distinguishing these diseases is a very critical problem for subsequent treatment. The patient may be clinically silent in the early phase of DILD, but sometimes these symptoms may develop into a serious and fatal condition in certain agents (e.g. leflunomide, gefitinib), so careful observation is needed and the early detection of an abnormal shadow is critical in order to
